BHP Group Half-Year Profit Surges as Copper Overtakes Iron Ore on AI-Driven Demand 
Anthropic’s Claude AI Reportedly Used in U.S. Operation to Capture Nicolas Maduro 
Freedom Finance and Binance Join Forces in Digital Assets 
Anderson Cooper to Exit CBS News’ 60 Minutes After Nearly 20 Years 
Sachem Head Boosts Warner Bros. Discovery Stake Amid Netflix Deal and Paramount Bid 
Bain Capital Secures RBI Approval to Acquire Up to 41.7% Stake in Manappuram Finance 
Federal Court Fines Mobil Oil Australia A$16 Million for Misleading Fuel Claims 
Mitsui Kinzoku Stock Surges to Record High After Profit Forecast Upgrade and Dividend Increase 
Ireland’s Data Protection Commission Launches GDPR Investigation Into X’s AI Chatbot Grok 
OpenAI Hires OpenClaw Creator Peter Steinberger to Advance Next-Generation AI Agents 
Anduril Eyes $60 Billion Valuation in New Funding Round to Expand Defense Manufacturing and Autonomous Fighter Jet Development 
Macquarie-Led Consortium to Acquire Qube Holdings in A$11.7 Billion Deal 
Valero Energy Expands Venezuelan Crude Imports as U.S. Sanctions Ease 
BlueScope Steel Forecasts Stronger Second-Half Earnings, Shares Rise Above Rejected Buyout Offer 
Starboard Value Targets Tripadvisor Board Overhaul Amid Stock Slump 
Thomas Pritzker to Step Down as Hyatt Executive Chairman After Epstein Ties Acknowledged 
EMERYVILLE, Calif., April 26, 2018 -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the company will report first quarter 2018 financial results on Thursday, May 3, 2018, after market close. Subsequently, Adamas’ management team will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update.
Investor Conference Call and Webcast
The conference call can be accessed by dialing 844-215-3280 for participants in the U.S. or Canada and 484-747-6383 for international callers. The webcast can be accessed live via the investor section of the Adamas website at http://ir.adamaspharma.com/events-presentations and will be available for replay until June 3, 2018.
About Adamas Pharmaceuticals, Inc.
Adamas’ goal is to create and commercialize a new generation of medicines intended to lessen the burden of chronic neurologic diseases on patients, caregivers and society using its deep understanding of time-dependent biology. The company is focused on the commercial launch of GOCOVRI™ (amantadine) extended release capsules (previously ADS-5102), the first and only medicine approved by the U.S. Food and Drug Administration for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, and delivering on its pipeline of differentiated investigational programs. Those programs include: ADS-5102 in development for the treatment of multiple sclerosis walking impairment; and ADS-4101, a high-dose, modified release lacosamide in development for the treatment of partial onset seizures in patients with epilepsy. For more information about Adamas and its unique approach to developing medicines based on time-dependent biology, please visit www.adamaspharma.com.
Contact: Ashleigh Barreto Director, Corporate Communications & Investor Relations Adamas Pharmaceuticals, Inc. 510-450-3567 [email protected]
